biodexa-logo-square (1).png
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
February 13, 2025 08:30 ET | Biodexa Pharmaceuticals PLC
February 13, 2025 Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 Biodexa Pharmaceuticals PLC invites individual and institutional investors as well as...
biodexa-logo-square (1).png
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
February 10, 2025 08:30 ET | Biodexa Pharmaceuticals PLC
February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or...
biodexa-logo-square (1).png
Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer
January 22, 2025 08:30 ET | Biodexa Pharmaceuticals PLC
January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a...
biodexa-logo-square (1).png
Result of General Meeting
November 22, 2024 08:30 ET | Biodexa Pharmaceuticals PLC
November 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage...
biodexa-logo-square (1).png
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq
November 12, 2024 08:48 ET | Biodexa Pharmaceuticals PLC
November 12, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage...
biodexa-logo-square (1).png
Notice of General Meeting
November 07, 2024 16:30 ET | Biodexa Pharmaceuticals PLC
November 7, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing...
biodexa-logo-square (1).png
Biodexa Announces Successful Appeal of Nasdaq Delisting
October 15, 2024 16:15 ET | Biodexa Pharmaceuticals PLC
Exhibit 99.1 October 15, 2024 Biodexa Announces Successful Appeal of Nasdaq Delisting Biodexa Pharmaceuticals PLC. (the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage...
biodexa-logo-square (1).png
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
October 04, 2024 08:30 ET | Biodexa Pharmaceuticals PLC
October 4, 2024 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Cohort A Data on Overall Survival Compare Favorably with...
biodexa-logo-square (1).png
Interim results for the six months ended June 30, 2024
September 26, 2024 08:30 ET | Biodexa Pharmaceuticals PLC
September 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an...
biodexa-logo-square (1).png
ADR Ratio Change
September 19, 2024 16:30 ET | Biodexa Pharmaceuticals PLC
September 19, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical...